Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xilio Therapeutics (XLO) Non-Current Deffered Revenue (2024 - 2025)

Historic Non-Current Deffered Revenue for Xilio Therapeutics (XLO) over the last 2 years, with Q3 2025 value amounting to $25.5 million.

  • Xilio Therapeutics' Non-Current Deffered Revenue rose 20358.38% to $25.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.5 million, marking a year-over-year increase of 20358.38%. This contributed to the annual value of $19.3 million for FY2024, which is N/A changed from last year.
  • As of Q3 2025, Xilio Therapeutics' Non-Current Deffered Revenue stood at $25.5 million, which was up 20358.38% from $28.6 million recorded in Q2 2025.
  • Xilio Therapeutics' Non-Current Deffered Revenue's 5-year high stood at $38.7 million during Q1 2025, with a 5-year trough of $8.4 million in Q3 2024.